The main cause of death globally remains debilitating heart conditions, such as dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), which are often due to mutations of specific components of adhesion complexes. Vinculin regulates these complexes and plays essential roles in intercalated discs that are necessary for muscle cell function and coordinated movement and in the development and function of the heart. Humans bearing familial or sporadic mutations in vinculin suffer from chronic, progressively debilitating DCM that ultimately leads to cardiac failure and death, whereas autosomal dominant mutations in vinculin can also provoke HCM, causing acute cardiac failure. The DCM/HCM-associated mutants of vinculin occur in the 68-residue insert unique to the muscle-specific, alternatively spliced isoform of vinculin, termed metavinculin (MV). Contrary to studies that suggested that phosphoinositol-4,5-bisphosphate (PIP 2 ) only induces vinculin homodimers, which are asymmetric, we show that phospholipid binding results in a domain-swapped symmetric MV dimer via a quasi-equivalent interface compared with vinculin involving R975. Although one of the two PIP 2 binding sites is preserved, the symmetric MV dimer that bridges two PIP 2 molecules differs from the asymmetric vinculin dimer that bridges only one PIP 2 . Unlike vinculin, wild-type MV and the DCM/ HCM-associated R975W mutant bind PIP 2 in their inactive conformations, and R975W MV fails to dimerize. Mutating selective vinculin residues to their corresponding MV residues, or vice versa, switches the isoform's dimeric constellation and lipid binding site. Collectively, our data suggest that MV homodimerization modulates microfilament attachment at muscular adhesion sites and furthers our understanding of MV-mediated cardiac remodeling.
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cardiomyopathy | cell adhesion | cytoskeleton | metavinculin | vinculin C ardiomyopathies are a major worldwide health problem, with patients often suffering cardiac arrest and premature death. Over the past decade, several inherited and sporadic mutations in genes encoding components of adhesion complexes and of intercalated discs, which are required for the coordinated movement of heart tissue, have been pinpointed as the cause of many cardiomyopathies. Vinculin and its muscle-specific splice variant, metavinculin (MV), are essential and highly conserved cytoskeletal proteins that play critical regulatory roles in cell-cell adherens-type junctions and cell-matrix focal adhesions (1) (2) (3) . Both isoforms localize to the cell membrane, the I band in the sarcomere, and to intercalated discs (4) . MV is coexpressed with vinculin (5) and colocalizes with vinculin in cardiac myocytes (6) . MV only differs from vinculin by an insertion of 68 residues between α-helices H1 and H2 of the 5-helix bundle vinculin tail domain Vt (5, 7), whereby H1′ of the insert of MV structurally replaces H1 of vinculin. Several MV mutations have been shown to be associated with dilated cardiomyopathies (DCMs) and hypertrophic cardiomyopathies (HCMs) in human (8) (9) (10) , where they disrupt intercalated discs in the hearts of afflicted patients (8, 9) , resulting in improper force generation and stress-induced phenotype in the heart. Reduced meta/vinculin expression leads to abnormal myocytes, which predispose to stress-induced cardiomyopathy (11) . The missense mutation R975W present in the MV-specific insert is associated with both DCM and HCM phenotypes and alters the organization of intercalated discs in vivo. This mutation has been suggested to compromise the interactions of MV with its partners, including vinculin (10) .
Both vinculin isoforms are held in a closed, inactive conformation through extensive hydrophobic interactions of the meta/vinculin head (VH) and C-terminal Vt (or MVt in MV) domains, which are connected via a flexible proline-rich linker (12) (13) (14) (15) (16) (17) . The intramolecular head-tail association regulates the binding of a large number of proteins, including talin (18), α-actinin (19), or α- (20) and β-catenin (21) to VH, and F-actin (22, 23) , phosphoinositol-4,5-bisphosphate (PIP 2 ) (24), and raver1 (25) to Vt or MVt. Further, the proline-rich hinge binds to the vasodilator-stimulated phosphoprotein VASP, vinexin-β, and the Arp2/3 complex to control actin dynamics at adhesion sites and thus cell migration (26) (27) (28) . Our structures of activated vinculin in complex with the vinculin binding sites (VBSs) of talin (14, 15, 29, 30) , α-actinin (16), or IpaA (31) (32) (33) showed that binding of these VBSs severs the vinculin head-tail interaction and displaces Vt allosterically. Originally, PIP 2 was thought to sever the VH-Vt interaction (34) (35) (36) , but the VBSs of talin and α-actinin, or those of the IpaA invasin of Shigella, are sufficient to activate vinculin, whereas mechanical stretching of a single talin molecule activates vinculin (37) . More recently, our vinculin/PIP 2 dimer structure showed that the VH and PIP 2 binding sites on Vt are distinct (38) .
Significance
Debilitating heart conditions, dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM), are often due to inherited or acquired mutations in genes that encode specific components of adhesion complexes. In muscle tissue, some of these adhesion complexes have specialized structures, called intercalated discs, which are important for contraction and coordinated movement. Here we provide molecular insights into the cytoskeletal protein metavinculin, which is necessary for the proper development and maintenance of heart tissue and is mutated in human DCM and HCM. We show that the binding of lipid causes metavinculin to dimerize and involves a specific metavinculin amino acid associated with severe DCM/HCM. Collectively, our studies provide insight into how such metavinculin mutations in components of adhesion complexes lead to cardiomyopathies.
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Vinculin oligomerization amplifies its interactions with other adhesion proteins, yet the observed PIP 2 -induced oligomerization (26, (39) (40) (41) might have been the result of an artifact of crosslinking and the physiological lipid-induced vinculin oligomer seems to be the dimer (42) . In the Vt/PIP 2 crystal structure, one PIP 2 molecule is sandwiched between three Vt molecules, whereby two Vt subunits engage in a domain swap-like arrangement of their C-terminal coiled-coil regions (38) . We showed that PIP 2 binding is necessary for organizing stress fibers, for maintaining optimal focal adhesions and for cell migration and spreading, and that PIP 2 binding is necessary for the control of vinculin dynamics and turnover in focal adhesions (38) .
Here we provide mechanistic insight into PIP 2 -induced MV dimerization. We show that in contrast to previous reports, PIP 2 binding induces MV homodimerization via a domain swap-like arrangement of the C termini. Although one of the two PIP 2 binding sites is preserved in both isoforms, the symmetric MVt dimer, which binds two PIP 2 molecules, differs from the asymmetric Vt dimer, which binds one PIP 2 , mainly due to the presence of the MVt-specific, DCM/HCM-associated R975 residue. In contrast to vinculin, which only binds PIP 2 in its activated, open form, MV binds PIP 2 also in its inactive, closed conformation. However, dimerization is only possible for activated MV, and the DCM/HCMassociated mutant MV does not dimerize even when activated. Collectively, we provide important insights into how dimerization of MV contributes to the stabilization of adhesion complexes.
Results
Architecture of the PIP 2 -Bound MV Structure. Although MV was thought to be impaired in dimerizing, our MVt/PIP 2 crystal structure (SI Appendix, Tables S1 and S2) shows that each MVt molecule forms a domain-swapped dimer, whereby the C terminus of one subunit reaches into a pocket of the twofoldrelated MVt (Fig. 1A) . Specifically, W1132 stacks with H974, and Y1133 interacts with R1003 (where the underline throughout the text denotes that the residue is from a symmetry-related subunit). Residues 1131-1134 are necessary for lipid-induced dimer formation, as the MVt Δ1131-1134 binds PIP 2 without dimerization in the crystal (Fig. 1B and SI Appendix, Tables S1 and S2) or in solution (42) . This region is disordered in the unbound MVt and full-length MV structures (13) . In the MVt/PIP 2 structure, residues 1116-1123 following the last α-helix H5 interact with the C terminus of α-helix H3 (residue 1039), whereas this region is disordered in the unbound MVt structure, interacting instead with the proline-rich region in the full-length structures (12, 13) .
MVt has two nanomolar binding sites for Vt/PIP 2 mediated by PIP 2 (42) and indeed two PIP 2 molecules were bound to MVt and MVt Δ1131-1134 ( Fig. 1 A and B) . One PIP 2 binding site (SI Appendix, Fig. S1A ) is formed by the C terminus of α-helix H5, involving R1107 and E1110 and the C-terminal coiled coil, in particular R1128, as well as the C terminus of α-helix H1′, whereby R975, which is mutated to a tryptophan in DCM/HCM, engages in electrostatic interactions with the PIP 2 5′-phosphate group. K979 and R1128 additionally bind the PIP 2 4′-and 5′-phosphate groups. A second PIP 2 binding site is provided by N-terminal residues of α-helix H3, where K1012 and R1013 bind PIP 2 (SI Appendix, Fig. S1B ). Collectively, PIP 2 induces dimerization of MVt and residues 1131-1134 are necessary for lipid-induced MVt dimerization but not for lipid binding.
The DCM/HCM-Associated R975W Mutation Prevents Lipid-Induced MV Dimerization. The missense mutation R975W is associated with both DCM and HCM phenotypes, alters the organization of intercalated discs in vivo, and has been suggested to compromise the interactions of MV with its partners, including vinculin (10). We found that R975W prevents homodimerization (Fig. 1C) due to its bulkier tryptophan side chain. Whereas the R975W fivehelix bundle remains essentially the same, the H4-H5 loop (residues 1037-1080) and significantly the C terminus (residues 1132-1134), which is domain swapped in wild-type MVt, are disordered in the MVt R975W/PIP 2 structure. This causes the lipid to bind the mutant ∼5 Å away from its corresponding wildtype binding site (Fig. 1C) . Further, one PIP 2 is bound in the monomeric R975W structure (versus two in the wild-type dimer interface), which might explain the molecular basis of the most severe DCM/HCM-associated MV mutant. Interestingly, in our apo MVt R975W crystal structure (SI Appendix, Tables S3 and S4), Q1134 and W1132 stack with H974 intramolecularly (SI Appendix, Fig. S2 ), whereas W1132 instead stacks with H974 intermolecularly in the PIP 2 -induced dimer structure. Collectively, this finding suggests that PIP 2 first induces the release of the C terminus, which then induces dimerization.
Based on our PIP 2 -bound MVt and MVt Δ1131-1134 crystal structures, we generated an exhaustively large number of mutants that should be deficient in binding to PIP 2 . Unfortunately, whereas point mutations were easy to generate, mutating key residues of both PIP 2 binding sites (R975, K979, K1012, R1013, R1107, and R1128) resulted in precipitation that precluded obtaining interpretable binding results. Further, a quadruple MVt mutant targeting the domain-swapped dimerization region (R975Q, K979Q, R1107Q, and R1128Q) still bound PIP 2 (as did all mutants that were soluble), given the availability of the second PIP 2 binding site (SI Appendix, Fig. S1C ). All mutant proteins are functional and bind to F-actin (SI Appendix, Fig. S1D ). We solved the crystal structure of this quadruple mutant in the presence of PIP 2 (SI Appendix, Tables S1 and S2) and found no electron density for PIP 2 , and the mutant MVt did not engage in dimer interactions (Fig. 1D) . Significantly, in the mutant structure the C terminus folds back to almost occupy the space filled by PIP 2 in the wild-type structure. The fact that the second lipidbinding site involving K1012 and R1013 is occupied by crystal contacts instead suggests that the second binding site is weaker. Indeed, PIP 2 bound to MVt with binding affinities of 0.7 and 59 μM, respectively, for the two sequential binding sites (Fig.  1E) . On the other hand, in agreement with the crystal structure, the DCM/HCM-associated MVt R975W mutant showed a single binding site in solution (Fig. 1F) . Consistently, the mechanisms of wild type and MVt R975W binding to PIP 2 differ thermodynamically; whereas both are characterized by a negative Gibbs free energy (ΔG), the binding of PIP 2 to MVt R975W is entropically driven, whereas for wild type, it is both entropically and enthalpically driven (SI Appendix, Table S5 ). Because R975 is mutated in both the quadruple mutant (to a Gln) and in the DCM/HCM-associated mutant (to a Trp) resulting in PIP 2 -bound but monomeric structures, we conclude that R975 is necessary for lipid-induced MVt dimerization but not for lipid binding.
We confirmed the lipid-induced MVt dimerization in solution (Fig. 2) by using CFP-and YFP-tagged FRET probes as donoracceptor pairs. For wild-type MVt, we observed a significant increase in emission peaks in the presence of lipid at 526 nm, indicating the energy transfer between the donor CFP-MVt and the acceptor YFP-MVt ( Fig. 2A) . In contrast, the three mutants that are monomeric in the crystal show similar emission spectra in the absence or with increasing amounts of PIP 2 , indicating that PIP 2 does not induce dimerization (Fig. 2 B-D) . Whereas the DCM/HCM-associated mutant R975W shows some FRET (<5% compared with wild type), the emission spectra of the FRET signal in the absence of PIP 2 shows a spectral bleed through at 526 nm, which overlays with the emission spectra at the same wavelength for the CFP and YFP FRET pairs in the presence of PIP 2 . As FRET pairs are sensitive to both orientation and localization, the minimal FRET contributed by this DCM/HCM-associated mutant suggests the proximity of molecules due to nonspecific interactions.
The Lipid-Induced Asymmetric Vinculin and Symmetric MV Dimer
Interactions Are Quasi-Equivalent. Comparison of both dimeric vinculin isoforms reveals that the MVt dimer is symmetric (180°s ubunit rotation), whereas the Vt dimer is asymmetric (∼160°/ 200°rotation). Whereas the lipid-induced domain swap is similar in the two vinculin isoforms (involving in particular the stacking of W1064 and H906 in Vt or equivalent W1132 and H974 in MVt), there are two PIP 2 molecules bound to one face of the MVt dimer interface (Fig. 3A) , while there is only one PIP 2 ( Fig. 3B) bound to the opposite face of the Vt dimer interface (Fig. 3C) , suggesting that the Vt and MVt dimers bind the membrane in opposite orientations. Superposition of one Vt onto one MVt subunit results in a relative movement of about 75°for the second tail domains (Fig. 3C) , reflected in distinct buried surface areas for MVt (∼488 Å 2 ) and Vt (∼515 Å 2 ) dimers. Strikingly, with the exception of MVt residue R975, which is mutated in DCM/HCM, all Vt and MVt residues involved in binding PIP 2 are conserved (Fig. 3D and SI Appendix, Fig. S3A ). Further, in the MVt/PIP 2 dimer interface, PIP 2 binds to residues R975, K979, R1107, and R1128 (SI Appendix, Fig. S3 B and C) and of these four residues, only R975 is not conserved. In Vt, this position is occupied by an aspartate, which changes the electrostatic surface potential and thus the lipid-binding site (Fig. 3 E  and F) . Similarly to the principles of quasi-equivalence formulated by Caspar and Klug (43) to explain the architecture of virus capsids, distinct Vt and MVt dimers seem to be obtained by equivalent and quasi-equivalent interactions (SI Appendix, Table  S6 ). Whereas Caspar and Klug (43) explained the architecture of virus particles with quasi-equivalent pentamers and hexamers from identical subunits, this idea has already been expanded to subunits with similar but not identical sequence with cubic or dodecahedral symmetry (44) . In the case of meta/vinculin, there are only 11 residues that are different in the two 175-residue polypeptide chains (SI Appendix, Fig. S3A ). Aside from MVt residue R975 mentioned above, only Vt residues R903 and R910 engage in intermolecular interactions, whereas the corresponding residues in MVt (Q971 and T978) are solvent exposed. Indeed, mutating these MV residues to the corresponding vinculin residues (Q971R, R975D, and T978R) converts the symmetric MVt into an asymmetric Vt-like dimer with only one sandwiched PIP 2 (Fig. 3G) . Likewise, mutating vinculin residues to the corresponding MV residues (R903Q, D907R, and R910T) converts the asymmetric Vt, where the two subunits are related by an ∼160°/200°rotation, into a symmetric MVt-like dimer with two sandwiched PIP 2 molecules (Fig. 3H) , where the two subunits are related by a crystallographic 180°dyad. In another example of quasi-equivalent interactions, the mutated Vt dyad is slightly rotated compared with the MVt dyad (Fig. 3H) , whereby the C termini (residues 1064-1066) are disordered, perhaps due to weaker secondary PIP 2 binding (Fig. 1E) . Thus, Vt residues R903, D907, and R910 and the corresponding MVt residues Q971, R975, and T978 are unique and dictate the symmetry of the dimer.
Equivalent and quasi-equivalent interactions are also seen for the second PIP 2 binding site on α-helix H3. In the Vt/PIP 2 structure, a third Vt molecule binds the PIP 2 molecule via conserved K944 and R945. Significantly, mutating these residues to glutamines decreased the lipid binding capacity of Vt by 90% (38) . This interaction is similar to that seen in the MVt/PIP 2 structure (SI Appendix, Fig. S4 ). However, whereas PIP 2 in Vt interacts with three Vt subunits and in particular with two K915 provided by two Vt subunits, in the MVt/PIP 2 structure, the lipid only interacts with the conserved K983 (corresponding to vinculin residue K915) via crystal contacts.
The Lipid-Induced MV Dimerization Affects the Actin Cytoskeleton and Cell Migration. To investigate the physiological role of lipidinduced MV dimerization, we exogenously expressed wildtype and monomeric Δ1131-1134 and DCM/HCM-associated R975W mutant GFP-tagged MV in vinculin-null cells. Confocal immunofluorescence studies demonstrated that wild-type MV reestablished a well-organized actin network (SI Appendix, Fig. S5 ). In contrast, whereas the expression of the monomeric GFP-MV Δ1131-1134 and R975W mutants resulted in localization to focal adhesions, their spreading was diminished and chaotic and they were impaired in restoring the actin cytoskeleton network.
Furthermore, to determine the effects of the lipid-induced dimerization on focal adhesions in these cells, we performed scratch-wound healing assays (SI Appendix, Fig. S6 ). Expression of wild-type MV suppressed the enhanced but chaotic wound closure typical of vinculin-null cells and led to a tighter closure of the wound. Cells expressing wild-type vinculin close a wound in 12-14 h (38), whereas the wild-type MV expressing mouse embryonic fibroblast cells showed 80-90% closure in 16 h, indicating that MV regulates focal adhesion turnover more tightly. In contrast, forced expression of dimerization-deficient Δ1131-1134 and R975W MV mutants led to rapid wound closure like vinculin-null cells, suggesting that focal adhesion turnover is not properly regulated.
Discussion
Vinculin is a key cytoskeletal adaptor protein that regulates cell adhesion and migration by linking the actin cytoskeleton to adhesion receptor complexes in cell adhesion sites. Dimerization is crucial for vinculin function because vinculin dimerization is required for and results in actin filament bundling (25, 36, 45) . Thus, control of Vt conformation and dimerization are crucial for protein function in cell adhesion sites. Binding of PIP 2 to the meta/vinculin tail domains results in a conformational change in MVt and Vt and dimer formation, whereby the disordered C termini bind to the first α-helix (H1′ and H1, respectively) of another five-helix bundle tail domain. This domain-swapped intermolecular interaction is strengthened by a tryptophan from one meta/vinculin molecule stacking onto a histidine from another meta/vinculin subunit. Significantly, R975 residing on α-helix H1′ in MV that binds to PIP 2 is replaced by an aspartate in vinculin that is not involved in PIP 2 binding to Vt and is the only amino acid that is not conserved in all combined, MVt or Vt, lipid binding residues in the crystal structures (46) . Importantly, the DCM/HCM-associated mutant R975W binds PIP 2 but does not dimerize. Thus, it seems that R975 in MV (or D907 in vinculin) dictates the type of dimer interaction induced by PIP 2 binding and the difference in lipid-bound vinculin versus MV dimers resulting from equivalent and quasi-equivalent intermolecular interactions.
Next, deletion of the five C-terminal residues in Vt did not abrogate its ability to bind to PIP 2 (47) . Similarly, in our MVt Δ1131-1134 structure bound to PIP 2 , the lipid binding remains as seen in our wild-type MVt/PIP 2 structure, yet in the absence of W1132, which stacks intermolecularly with H974 in the wild-type structure, the truncated MVt/PIP 2 remains monomeric in the crystal and in solution (42) . Thus, the C terminus seems necessary for lipid-induced dimerization but dispensable for lipid binding. Likewise, mutating the four PIP 2 binding residues near the dimer interface results in a monomeric unbound mutant MVt structure, supporting the notion that lipid binding induces dimerization.
At focal adhesions, integrin binding to the extracellular matrix triggers mechanical force on associated talin molecules that exposes VBSs that activate vinculin, allowing binding to F-actin and thereby stabilizing nascent cell-matrix adhesions (48) (49) (50) . Several mechanisms, binding partners, and modifications have been reported to sever the vinculin head-tail interaction and activate vinculin (46, 51) . Lipids were originally thought to be involved in activating vinculin (34, 36) but inactive vinculin does not bind to PIP 2 (38) . Additionally, unlike for vinculin, the PIP 2 binding site is accessible in the closed MV structure. Indeed, we obtained binding of PIP 2 to full-length MV and the DCM/HCM R975W MV mutant (Fig. 4 A-C) . Interestingly, the DCM/HCMassociated R975W mutant binds PIP 2 with sixfold increased affinity (53 μM versus 313 μM).
Collectively, our data provide significant advances in our understanding of meta/vinculin dimerization, activation, and membrane attachment and important insights into the most severe DCM/HCM-associated MV mutant. We propose a mechanism where activated MV dimerizes at the cell membrane (Fig.  4D) , whereas in DCM/HCM, inactive and active MV R975W bind the membrane without dimerizing, resulting perhaps in a decreased ability to stabilize cell adhesions. This model is supported by our observations that, in contrast to wild-type MV, expression of the R975W mutant in vinculin-null cells does not restore a wellorganized actin cytoskeleton network and does not rescue the wound closure phenotype. Vinculin has recently been shown to reinforce the myocardial cytoskeleton, thereby improving contractility and prolonging life (52, 53) . Our mechanistic insights will aid the development of drug therapies that strengthen the hearts of patients suffering from age-related heart failure.
Materials and Methods
Sample Preparation and Assays. DNA constructs, sample preparation, and biochemical and cell biological analyses are described in SI Appendix, SI Materials and Methods.
X-Ray Crystallography. All six distinct MVt/PIP 2 crystals were obtained by using polyethylene glycol 3350 as the precipitating agent, whereas the mutant Vt/PIP 2 crystals grew from 1.5 M lithium sulfate. Except for the MVt/ PIP 2 crystals that were cryoprotected in perfluoropolyether, all crystals were soaked in mother liquor that was supplemented with 25% glycerol. All X-ray diffraction data were collected at the Advanced Photon Source at Argonne National Laboratory beam lines 22ID and 22BM or Stanford Synchrotron Radiation Lightsource 12-2 and integrated and scaled using XDS and SCALA as implemented in autoPROC (54) . Phases for all six distinct MVt/PIP 2 structures were calculated from a molecular replacement solution of the apo MVt structure (13) , whereas the Vt structure in its tail-bound state (14) was used for the mutant Vt/PIP 2 structure determination. Crystallographic refinement of all structures was performed using autoBUSTER (55) . 
